dupilumab CRSwNP
Selected indexed studies
- Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. (Lancet, 2019) [PMID:31543428]
- Dupilumab in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP): A multicentric observational Phase IV real-life study (DUPIREAL). (Allergy, 2023) [PMID:37203259]
- Dupilumab-induced hypereosinophilia: review of the literature and algorithm proposal for clinical management. (Expert Rev Respir Med, 2022) [PMID:35703018]
_Worker-drafted node — pending editorial review._
Connections
dupilumab CRSwNP is a side effect of
Sources
- Dupilumab-induced hypereosinophilia: review of the literature and algorithm proposal for clinical management. (2022) pubmed
- Dupilumab Versus Mepolizumab for Chronic Rhinosinusitis With Nasal Polyposis: An Indirect Treatment Comparison. (2024) pubmed
- Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. (2019) pubmed
- Dupilumab in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP): A multicentric observational Phase IV real-life study (DUPIREAL). (2023) pubmed
- Chronic rhinosinusitis with nasal polyps (CRSwNP) treated with omalizumab, dupilumab, or mepolizumab: A systematic review of the current knowledge towards an attempt to compare agents' efficacy. (2024) pubmed
- Two-year results of tapered dupilumab for CRSwNP demonstrates enduring efficacy established in the first 6 months. (2023) pubmed
- Clinical management of dupilumab-induced blood eosinophilia in CRSwNP: a practical algorithm. (2025) pubmed
- Dupilumab response onset, maintenance, and durability in patients with severe CRSwNP. (2024) pubmed
- Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases. (2021) pubmed
- Conjunctivitis in dupilumab clinical trials. (2019) pubmed